Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 413 Lymphoma 401 Lymphoma, Non-Hodgkin 337 Leukemia, Lymphocytic, Chronic, B-Cell 302 Lymphoma, Follicular 295 Lymphoma, Mantle-Cell 225 Lymphoma, B-Cell, Marginal Zone 159 Leukemia 119 Lymphoma, B-Cell 112 Burkitt Lymphoma 110 Waldenstrom Macroglobulinemia 99 Precursor Cell Lymphoblastic Leukemia-Lymphoma 90 Recurrence 83 Hodgkin Disease 60 Lymphoma, Large-Cell, Immunoblastic 57 Neoplasms 39 Multiple Myeloma 26 Lymphoma, Large-Cell, Anaplastic 26 Myelodysplastic Syndromes 25 Leukemia, Myeloid, Acute 24 Dendritic Cell Sarcoma, Interdigitating 22 Hematologic Neoplasms 21 Leukemia, Hairy Cell 20 Intraocular Lymphoma 17 Leukemia, Prolymphocytic 16 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 14 Lymphoma, T-Cell 14 Neoplasms, Plasma Cell 13 Lymphoproliferative Disorders 12 Hematologic Diseases 12

Interventions

fludarabine 2 Cyclophosphamide 2 Rituximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Myositis × Rituximab × Clear all

NCT00774462 2012-12-11

FORCE

Assistance Publique - Hôpitaux de Paris

Phase 2 Completed

Myasthenia Gravis, Myositis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡